The stock of Aduro BioTech Inc (NASDAQ:ADRO) is a huge mover today! About 188,251 shares traded hands. Aduro BioTech Inc (NASDAQ:ADRO) has declined 30.13% since April 4, 2016 and is downtrending. It has underperformed by 31.22% the S&P500.
The move comes after 5 months positive chart setup for the $680.44M company. It was reported on Nov, 4 by Barchart.com. We have $15.55 PT which if reached, will make NASDAQ:ADRO worth $299.39M more.
Analysts await Aduro BioTech Inc (NASDAQ:ADRO) to report earnings on November, 28. They expect $-0.49 earnings per share, down 5,000.00% or $0.50 from last year’s $0.01 per share. After $0.03 actual earnings per share reported by Aduro BioTech Inc for the previous quarter, Wall Street now forecasts -1,733.33% negative EPS growth.
Aduro BioTech Inc (NASDAQ:ADRO) Ratings Coverage
Out of 6 analysts covering Aduro Biotech (NASDAQ:ADRO), 3 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 50% are positive. Aduro Biotech has been the topic of 9 analyst reports since August 19, 2015 according to StockzIntelligence Inc. The rating was upgraded by Zacks to “Hold” on Thursday, September 3. The stock of Aduro BioTech Inc (NASDAQ:ADRO) earned “Buy” rating by TH Capital on Tuesday, November 24. Oppenheimer initiated Aduro BioTech Inc (NASDAQ:ADRO) rating on Tuesday, October 20. Oppenheimer has “Outperform” rating and $30 price target. The stock of Aduro BioTech Inc (NASDAQ:ADRO) has “” rating given on Wednesday, August 19 by Leerink Swann. As per Thursday, August 27, the company rating was maintained by Roth Capital. Oppenheimer downgraded the shares of ADRO in a report on Tuesday, December 1 to “Perform” rating. The rating was maintained by Roth Capital with “Buy” on Tuesday, November 24. As per Tuesday, May 17, the company rating was maintained by FBR Capital. The firm has “Underperform” rating by Bank of America given on Tuesday, March 15.
According to Zacks Investment Research, “Aduro Biotech, Inc. is an immunotherapy company. The Company develops technology and vaccines for the treatment of cancer and mesothelin-expressing tumors. Its product pipeline includes CRS-207, ADU-623, ADU-214, ADU-741, CDN and STINGVAX which are in different clinical trial. Aduro Biotech, Inc. is based in BERKELEY, United States.”
Another recent and important Aduro BioTech Inc (NASDAQ:ADRO) news was published by Fool.com which published an article titled: “Why Aduro Biotech Is Crashing Today” on November 24, 2015.
ADRO Company Profile
Aduro Biotech, Inc., incorporated on May 5, 2011, is a clinical-stage immunotherapy company. The Firm is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Firm has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies. The Company’s LADD technology platform is engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, LADD technology platform is being developed as a treatment for multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma. The Company’s STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a tumor-specific immune response. The Company’s B-select monoclonal antibody platform includes various immune modulating assets in research and preclinical development.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.